Thiard News@F4F

@newsen.bsky.social

6 days ago

Amgen Announces Successful Phase 3 Results for TEPEZZA in Thyroid Eye Disease Treatment Amgen has revealed optimistic topline results from a Phase 3 trial demonstrating the efficacy of TEPEZZA for thyroid eye disease via subcutaneous administration.

Amgen Announces Successful Phase 3 Results for TEPEZZA in Thyroid Eye Disease Treatment #United_States #Amgen #Thousand_Oaks #Thyroid_Eye_Disease #TEPEZZA

Thiard News@F4F

@newsen.bsky.social

1 week ago

Easton and Dick's Sporting Goods Revolutionize Retail with Spring Break Collection Drop Culture Easton and Dick's Sporting Goods redefine diamond sports retail through their innovative Spring Break Collection, combining exclusive drops with immersive retail experiences, appealing to modern youth athletes.

Easton and Dick's Sporting Goods Revolutionize Retail with Spring Break Collection Drop Culture #USA #Easton #DICK'S_Sporting_Goods #Thousand_Oaks #Spring_Break_Collection

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Amgen's Repatha® Successfully Reduces Cardiovascular Event Risks in Patients with Diabetes Recent findings reveal that Repatha® can lower the risk of major cardiovascular events by 31% in high-risk diabetic patients without significant atherosclerosis, marking a significant breakthrough in preventive care.

Amgen's Repatha® Successfully Reduces Cardiovascular Event Risks in Patients with Diabetes #USA #Amgen #Thousand_Oaks #Repatha #CVS

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Easton® Partners with Cosmic Baseball League: A New Era in Sports Gear Innovation Easton Diamond Sports has been named the official equipment partner of the Cosmic Baseball League, introducing vibrant, glowing gear to capitalize on this innovative new league.

Easton® Partners with Cosmic Baseball League: A New Era in Sports Gear Innovation #United_States #Thousand_Oaks #Cosmic_Baseball #Easton_Sports #Chili_Peppers

Thiard News@F4F

@newsen.bsky.social

1 month ago

Amgen to Showcase Innovations at the 2026 Global Healthcare Conference Amgen is set to participate in the upcoming Leerink Partners Global Healthcare Conference on March 11, 2026, sharing insights on their latest healthcare innovations.

Amgen to Showcase Innovations at the 2026 Global Healthcare Conference #United_States #Innovation #Healthcare_Conference #Amgen #Thousand_Oaks

Thiard News@F4F

@newsen.bsky.social

1 month ago

Amgen Declares $2.52 Dividend for the Second Quarter of 2026 Amgen's Board has declared a $2.52 per share dividend for Q2 2026, reflecting the company's strong performance and commitment to shareholders.

Amgen Declares $2.52 Dividend for the Second Quarter of 2026 #USA #Dividend #biotechnology #Amgen #Thousand_Oaks

Thiard News@F4F

@newsen.bsky.social

1 month ago

Amgen Set to Showcase Innovations at 46th Annual TD Cowen Health Care Conference Amgen will present at the TD Cowen Health Care Conference on March 2, 2026. Key executives will share insights on the company's advancements in healthcare technologies.

Amgen Set to Showcase Innovations at 46th Annual TD Cowen Health Care Conference #United_States #Amgen #Thousand_Oaks #Health_Care #TD_Cowen

Thiard News@F4F

@newsen.bsky.social

1 month ago

Amgen's UPLIZNA® Approved by European Commission for Treatment of Myasthenia Gravis The European Commission has granted approval for Amgen's UPLIZNA® as an additional treatment for generalized myasthenia gravis, offering hope to patients.

Amgen's UPLIZNA® Approved by European Commission for Treatment of Myasthenia Gravis #Amgen #Thousand_Oaks #Czech_Republic #Myasthenia_Gravis #UPLIZNA

Thiard News@F4F

@newsen.bsky.social

2 months ago

Amgen's UPLIZNA® Secures European Approval for Myasthenia Gravis Treatment Amgen's UPLIZNA® gains European Commission approval as an innovative treatment for generalized myasthenia gravis, providing long-term disease control.

Amgen's UPLIZNA® Secures European Approval for Myasthenia Gravis Treatment #United_Kingdom #Amgen #Thousand_Oaks #GMG #UPLIZNA®

Thiard News@F4F

@newsen.bsky.social

2 months ago

Amgen Reports Robust Financial Growth for 2025: Key Highlights from Fourth Quarter Results Amgen showcases impressive 2025 financial results, with double-digit revenue growth and record sales across multiple products, indicating strong market performance.

Amgen Reports Robust Financial Growth for 2025: Key Highlights from Fourth Quarter Results #United_States #financial_results #revenue_growth #Amgen #Thousand_Oaks

Thiard News@F4F

@newsen.bsky.social

2 months ago

Anchor Loans Achieves Unprecedented $5.4 Billion in Loan Originations for 2025 Anchor Loans announces a remarkable loan origination volume of $5.4 billion for 2025, marking a significant growth in the housing finance sector.

Anchor Loans Achieves Unprecedented $5.4 Billion in Loan Originations for 2025 #United_States #Real_Estate #Thousand_Oaks #Housing_Finance #Anchor_Loans

Thiard News@F4F

@newsen.bsky.social

3 months ago

Amgen's CEO to Address Key Innovations at the Upcoming 2026 J.P. Morgan Healthcare Conference On January 12, 2026, Amgen will showcase its latest innovations at the J.P. Morgan Healthcare Conference, led by CEO Robert A. Bradway, via an internet livestream.

Amgen's CEO to Address Key Innovations at the Upcoming 2026 J.P. Morgan Healthcare Conference #United_States #Healthcare_Conference #J.P._Morgan #Amgen #Thousand_Oaks

Thiard News@F4F

@newsen.bsky.social

3 months ago

Amgen's Strategic Move: Acquiring Dark Blue Therapeutics to Enhance Oncology Advancements Amgen has completed the acquisition of Dark Blue Therapeutics, adding a groundbreaking small molecule aimed at treating acute myeloid leukemia to its oncology portfolio.

Amgen's Strategic Move: Acquiring Dark Blue Therapeutics to Enhance Oncology Advancements #United_States #oncology #Amgen #Thousand_Oaks #Dark_Blue_Therapeutics

Thiard News@F4F

@newsen.bsky.social

3 months ago

Amgen Partners with U.S. Government to Make Medication Affordable for Patients Amgen collaborates with the U.S. government to lower drug prices for patients, expanding access through innovative programs.

Amgen Partners with U.S. Government to Make Medication Affordable for Patients #United_States #healthcare #Amgen #Thousand_Oaks #Drug_Pricing

Thiard News@F4F

@newsen.bsky.social

4 months ago

FDA Grants Approval for UPLIZNA®: A New Hope for Patients with Generalized Myasthenia Gravis Amgen's UPLIZNA® gains FDA approval, providing a targeted treatment for generalized myasthenia gravis with biannual dosing. This is a breakthrough for patients managing difficult symptoms.

FDA Grants Approval for UPLIZNA®: A New Hope for Patients with Generalized Myasthenia Gravis #United_States #Amgen #Thousand_Oaks #Myasthenia_Gravis #UPLIZNA

Thiard News@F4F

@newsen.bsky.social

4 months ago

Amgen Declares First Quarter 2026 Dividend of $2.52 Per Share Amgen announces a dividend of $2.52 per share for Q1 2026, payable on March 6 to shareholders of record by February 13.

Amgen Declares First Quarter 2026 Dividend of $2.52 Per Share #United_States #Dividend #Amgen #Thousand_Oaks #NASDAQ:AMGN

Thiard News@F4F

@newsen.bsky.social

4 months ago

FDA Approves IMDELLTRA® as Standard Therapy for Small Cell Lung Cancer Amgen's IMDELLTRA® has received full FDA approval for treating extensive stage small cell lung cancer, significantly improving survival rates.

FDA Approves IMDELLTRA® as Standard Therapy for Small Cell Lung Cancer #Amgen #Thousand_Oaks #SCLC #IMDELLTRA

Thiard News@F4F

@newsen.bsky.social

5 months ago

Amgen Declares a Fourth Quarter Dividend of $2.38 Per Share for 2025 Amgen has officially announced a dividend of $2.38 per share for the fourth quarter of 2025, showcasing their commitment to shareholders and innovative biotechnology.

Amgen Declares a Fourth Quarter Dividend of $2.38 Per Share for 2025 #United_States #Dividend #biotechnology #Amgen #Thousand_Oaks

Thiard News@F4F

@newsen.bsky.social

5 months ago

FDA Greenlights TEZSPIRE® as a New Hope for Chronic Rhinosinusitis with Nasal Polyps Amgen and AstraZeneca celebrate FDA approval of TEZSPIRE, a significant advancement in treating chronic rhinosinusitis with nasal polyps. This therapy targets TSLP, offering relief to millions.

FDA Greenlights TEZSPIRE® as a New Hope for Chronic Rhinosinusitis with Nasal Polyps #United_States #Amgen #Thousand_Oaks #TEZSPIRE #Allergy

Thiard News@F4F

@newsen.bsky.social

5 months ago

Lightfully Behavioral Health Earns Spot on America's 2025 Most Loved Workplaces List Discover how Lightfully Behavioral Health earned a place among America's Most Loved Workplaces for 2025, emphasizing employee satisfaction and care.

Lightfully Behavioral Health Earns Spot on America's 2025 Most Loved Workplaces List #United_States #Thousand_Oaks #Most_Loved_Workplaces #Employee_Satisfaction #Lightfully_Behavioral

Thiard News@F4F

@newsen.bsky.social

5 months ago

Lindsey Carnett Inspires Future Leaders at Cal Lutheran with Keynote Address Esteemed marketing leader Lindsey Carnett will deliver a keynote at California Lutheran University, discussing her entrepreneurial journey and insights on research-driven marketing strategies.

Lindsey Carnett Inspires Future Leaders at Cal Lutheran with Keynote Address #USA #Thousand_Oaks #California_Lutheran_University #Marketing_Maven #Lindsey_Carnett

Thiard News@F4F

@newsen.bsky.social

6 months ago

Amgen Launches AmgenNow Program to Offer Repatha at Reduced Prices Amgen unveils AmgenNow, a direct-to-patient initiative, providing Repatha at a significant discount in the U.S., aiming to enhance accessibility.

Amgen Launches AmgenNow Program to Offer Repatha at Reduced Prices #USA #Amgen #Thousand_Oaks #Repatha #AmgenNow

Thiard News@F4F

@newsen.bsky.social

6 months ago

Landmark Phase 3 Clinical Trial Shows Repatha's Efficacy in Preventing Cardiovascular Events Among High-Risk Patients The Phase 3 VESALIUS-CV trial reveals that Repatha significantly reduces cardiovascular events in high-risk patients without a history of heart issues, setting a new standard in heart disease prevention.

Landmark Phase 3 Clinical Trial Shows Repatha's Efficacy in Preventing Cardiovascular Events Among High-Risk Patients #USA #Amgen #Thousand_Oaks #Repatha #VESALIUS-CV

Thiard News@F4F

@newsen.bsky.social

6 months ago

Amgen Embarks on Major $650 Million Expansion in U.S. Manufacturing Sector Amgen has announced a significant investment of $650 million to expand its U.S. manufacturing network, paving the way for hundreds of new jobs.

Amgen Embarks on Major $650 Million Expansion in U.S. Manufacturing Sector #USA #biopharmaceuticals #Amgen #Thousand_Oaks #USA_manufacturing

Thiard News@F4F

@newsen.bsky.social

6 months ago

Lindsey Carnett Becomes First Executive Ambassador for Relay For Life in Conejo Valley Marketing Maven's Lindsey Carnett has been announced as the first Executive Ambassador for the American Cancer Society's Relay For Life in Conejo Valley.

Lindsey Carnett Becomes First Executive Ambassador for Relay For Life in Conejo Valley #United_States #Thousand_Oaks #American_Cancer_Society #Relay_For_Life #Lindsey_Carnett

Thiard News@F4F

@newsen.bsky.social

7 months ago

Join the Celebration: 2025 Relay For Life of Conejo Valley Marks 40 Years of Impact The 2025 Relay For Life of Conejo Valley will celebrate its 40th anniversary on September 27. Experience a fun-filled day dedicated to fighting cancer and honoring survivors.

Join the Celebration: 2025 Relay For Life of Conejo Valley Marks 40 Years of Impact #United_States #Thousand_Oaks #American_Cancer_Society #Conejo_Valley #Relay_For_Life

Thiard News@F4F

@newsen.bsky.social

7 months ago

Amgen and Kyowa Kirin Reveal Promising Top-Line Results from Rocatinlimab Phase 3 Study for Atopic Dermatitis The ASCEND study shows the potential of rocatinlimab as a long-term treatment for adults with moderate to severe atopic dermatitis, paving the way for innovative therapies.

Amgen and Kyowa Kirin Reveal Promising Top-Line Results from Rocatinlimab Phase 3 Study for Atopic Dermatitis #USA #Amgen #Thousand_Oaks #Kyowa_Kirin #Rocatinlimab

Thiard News@F4F

@newsen.bsky.social

7 months ago

24 Hour Fitness Partners with ISSA to Certify All General Managers as Personal Trainers 24 Hour Fitness, in a groundbreaking move, partners with ISSA to certify its General Managers as Personal Trainers, elevating club leadership standards.

24 Hour Fitness Partners with ISSA to Certify All General Managers as Personal Trainers #USA #Thousand_Oaks #24_Hour_Fitness #ISSA #Personal_Trainers

Thiard News@F4F

@newsen.bsky.social

7 months ago

Karen Hjerleid's Appointment as Chief Growth Officer at Lightfully Behavioral Health Karen Hjerleid has been appointed as the Chief Growth Officer at Lightfully Behavioral Health to lead growth initiatives and establish new partnerships.

Karen Hjerleid's Appointment as Chief Growth Officer at Lightfully Behavioral Health #United_States #mental_health #Thousand_Oaks #Lightfully_Health #Karen_Hjerleid

Thiard News@F4F

@newsen.bsky.social

7 months ago

Amgen's $600 Million Investment in Cutting-Edge Science and Innovation Center in California Amgen is set to invest over $600 million in a new science and innovation center at its California headquarters, boosting collaboration and job creation.

Amgen's $600 Million Investment in Cutting-Edge Science and Innovation Center in California #United_States #Innovation #Amgen #Thousand_Oaks #Biopharmaceutical